<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02070731</url>
  </required_header>
  <id_info>
    <org_study_id>DEFLECT III</org_study_id>
    <nct_id>NCT02070731</nct_id>
  </id_info>
  <brief_title>DEFLECT III: A Prospective, Randomized Evaluation of the TriGuard™ HDH Embolic Deflection Device During TAVI</brief_title>
  <acronym>TAVI</acronym>
  <official_title>A Prospective, Randomized Evaluation of the TriGuard™ HDH Embolic Deflection Device During Transcatheter Aortic Valve Implantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Keystone Heart</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Keystone Heart</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized evaluation of the TriGuard™ HDH embolic deflection device during transcatheter&#xD;
      aortic valve implantation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The TriGuard HDH device is an aortic embolism deflection device intended to reduce the amount&#xD;
      of embolic material that may enter the carotid, subclavian, and vertebral arteries during&#xD;
      transcatheter heart valve implantation.&#xD;
&#xD;
      To assess the safety, efficacy, and performance of the TriGuard HDH embolic deflection device&#xD;
      in patients undergoing transcatheter aortic valve implantation (TAVI), in comparison with&#xD;
      patients undergoing unprotected TAVI.&#xD;
&#xD;
      Subjects with indications for TAVI and who meet study eligibility criteria will be randomized&#xD;
      1:1 to one of two treatment arms:&#xD;
&#xD;
        -  Intervention - TAVI with the TriGuard HDH embolic deflection device&#xD;
&#xD;
        -  Control - standard unprotected TAVI&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>In hospital procedural safety</measure>
    <time_frame>Up to 7 days during post procedure hospitalization</time_frame>
    <description>In-hospital procedural safety, defined as the composite of the following Major Adverse Cardiovascular and Cerebrovascular Events (MACCE):&#xD;
All-cause mortality&#xD;
All stroke (disabling and non-disabling)&#xD;
Life threatening (or disabling) bleeding&#xD;
Acute kidney injury - Stage 2 or 3 (including renal replacement therapy)&#xD;
Major vascular complications</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">86</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <arm_group>
    <arm_group_label>unprotected TAVI</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>standard unprotected Transcatheter Aortic Valve Implantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAVI with the TriGuard HDH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAVI with the TriGuard HDH embolic deflection device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TriGuard HDH</intervention_name>
    <description>TAVI with the TriGuard HDH embolic deflection device</description>
    <arm_group_label>TAVI with the TriGuard HDH</arm_group_label>
    <other_name>TriGuard HDH embolic deflection device</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The patient is a male or non-pregnant female ≥18 years of age&#xD;
&#xD;
          -  Patient meets indications for TAVI&#xD;
&#xD;
          -  The patient is willing to comply with protocol-specified follow-up evaluations&#xD;
&#xD;
          -  The patient, or legally authorized representative, has been informed of the nature of&#xD;
             the study, agrees to its provisions and has provided written informed consent,&#xD;
             approved by the appropriate Medical Ethics Committee (EC) or Institutional Review&#xD;
             Board (IRB)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients undergoing TAVI via the trans-axillary, trans-subclavian, or trans-aortic&#xD;
             route&#xD;
&#xD;
          -  Patients undergoing TAVI via the transapical approach due to friable or mobile&#xD;
             atherosclerotic plaque in the aortic arch&#xD;
&#xD;
          -  Pregnant or nursing subjects and those who plan pregnancy in the period up to 1 year&#xD;
             following index procedure. Female subjects of child-bearing potential must have a&#xD;
             negative pregnancy test done within 7 days prior to index procedure per site standard&#xD;
             test&#xD;
&#xD;
          -  Patients with known diagnosis of acute myocardial infarction (AMI) within 72 hours&#xD;
             preceding the index procedure (according to definition) or AMI &gt;72 hours preceding the&#xD;
             index procedure, in whom creatine kinase and creatine kinase-Muscle Brain have not&#xD;
             returned to within normal limits at the time of procedure.&#xD;
&#xD;
          -  Patients who are currently experiencing clinical symptoms consistent with new-onset&#xD;
             AMI, such as nitrate-unresponsive prolonged chest pain&#xD;
&#xD;
          -  Patients with a history of bleeding diathesis or coagulopathy or patients in whom&#xD;
             anti-platelet and/or anticoagulant therapy is contraindicated, or who will refuse&#xD;
             transfusion&#xD;
&#xD;
          -  Patients with known other mental or physical illness or known history of substance&#xD;
             abuse that may cause non-compliance with the protocol, confound the data&#xD;
             interpretation, or is associated with a life expectancy of less than one year&#xD;
&#xD;
          -  Patients with severe allergy to heparin or known hypersensitivity or contraindication&#xD;
             to aspirin, heparin/bivalirudin, clopidogrel, nitinol, stainless steel alloy, and/or&#xD;
             contrast sensitivity that cannot be adequately pre-medicated&#xD;
&#xD;
          -  Patients with a history of a stroke or transient ischemic attack (TIA) within the&#xD;
             prior 6 months&#xD;
&#xD;
          -  Patients with an active peptic ulcer or history of upper gastrointestinal (GI)&#xD;
             bleeding within the prior 6 months&#xD;
&#xD;
          -  Patients with renal failure (estimated Glomerular Filtration Rate [estimated&#xD;
             Glomerular Filtration Rate] &lt;30 mL/min, calculated from serum creatinine by the&#xD;
             Cockcroft-Gault formula)&#xD;
&#xD;
          -  Patients with hepatic failure (Child-Pugh class C)&#xD;
&#xD;
          -  Patients with hypercoagulable states that cannot be corrected by additional&#xD;
             periprocedural heparin&#xD;
&#xD;
          -  Patients presenting with cardiogenic shock or severe hypotension (systolic blood&#xD;
             pressure &lt;90 mm Hg) at the time of the index procedure&#xD;
&#xD;
          -  Patients with severe peripheral arterial disease that precludes delivery sheath&#xD;
             vascular access&#xD;
&#xD;
          -  Patients with a heavily calcified or severely atheromatous aortic arch&#xD;
&#xD;
          -  Patients with an innominate artery ostium diameter &lt;11 mm&#xD;
&#xD;
          -  Patients with a transverse aortic diameter &gt;40 mm&#xD;
&#xD;
          -  Patients with anatomic irregularities of the aortic arch or innominate artery that&#xD;
             could prevent positioning and stability of the device&#xD;
&#xD;
          -  Patients with contraindication to cerebral MRI&#xD;
&#xD;
          -  Patients who have a planned treatment with any other investigational device or&#xD;
             procedure during the study period&#xD;
&#xD;
          -  Patients planned to undergo any other cardiac surgical or interventional procedure&#xD;
             (e.g., concurrent coronary revascularization) during the TAVI procedure or within two&#xD;
             (2) weeks prior to the TAVI procedure.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Baumbach, Md.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bristol Heart Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital de la Cavale Blanche</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chru-Lille</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique chez APHM</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxisklinik Herz Und Gefässe</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitäts-Herzzentrum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Care Center</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Städtische Kliniken Neuss</name>
      <address>
        <city>Neuss</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shaarey Tzedek</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ferrarotto hospital</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMC Utrecht</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Sussex County Hospital</name>
      <address>
        <city>Brighton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bristol Heart Institute</name>
      <address>
        <city>Bristol</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leeds General Infirmary</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <study_first_submitted>February 20, 2014</study_first_submitted>
  <study_first_submitted_qc>February 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2014</study_first_posted>
  <last_update_submitted>August 26, 2015</last_update_submitted>
  <last_update_submitted_qc>August 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TAVR</keyword>
  <keyword>TAVI</keyword>
  <keyword>Aortic Valve Stenosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

